Japan Approves IMCIVREE for Acquired Hypothalamic Obesity
RYTM sits 48% above its 52-week low of $74.5.
Summary
Japan's MHLW approved IMCIVREE (setmelanotide) for acquired hypothalamic obesity, opening a new commercial market for Rhythm. This follows the UK expanded authorization earlier this month and builds on the U.S. launch that drove Q2 revenue to $71.3M. The approval validates the drug's global regulatory path and adds a meaningful revenue stream in a market with high unmet need. Commercial launch in Japan is expected by end of 2026, pending final pricing determination.
At the time of this announcement, RYTM was trading at $110.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.